1. Home
  2. BRKR vs TGTX Comparison

BRKR vs TGTX Comparison

Compare BRKR & TGTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Bruker Corporation

BRKR

Bruker Corporation

HOLD

Current Price

$61.74

Market Cap

9.0B

Sector

Industrials

ML Signal

HOLD

Logo TG Therapeutics Inc.

TGTX

TG Therapeutics Inc.

HOLD

Current Price

$53.48

Market Cap

8.5B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
BRKR
TGTX
Founded
1960
1993
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Laboratory Analytical Instruments
Biotechnology: Pharmaceutical Preparations
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
9.0B
8.5B
IPO Year
2000
2008

Fundamental Metrics

Financial Performance
Metric
BRKR
TGTX
Price
$61.74
$53.48
Analyst Decision
Buy
Strong Buy
Analyst Count
13
5
Target Price
$48.54
$49.80
AVG Volume (30 Days)
1.9M
1.9M
Earning Date
05-06-2026
05-04-2026
Dividend Yield
0.58%
N/A
EPS Growth
N/A
1746.67
EPS
0.02
0.12
Revenue
$1,895,600,000.00
$2,785,000.00
Revenue This Year
$6.30
$49.08
Revenue Next Year
$3.81
$26.69
P/E Ratio
$3,144.50
$457.29
Revenue Growth
N/A
N/A
52 Week Low
$28.53
$25.37
52 Week High
$64.95
$59.30

Technical Indicators

Market Signals
Indicator
BRKR
TGTX
Relative Strength Index (RSI) 56.64 51.91
Support Level $54.54 $51.15
Resistance Level $64.18 $58.34
Average True Range (ATR) 3.05 2.23
MACD -0.03 -0.57
Stochastic Oscillator 74.63 36.41

Price Performance

Historical Comparison
BRKR
TGTX

About BRKR Bruker Corporation

Bruker Corp manufactures scientific instruments and diagnostic tests for customers in the life sciences, applied markets, pharmaceutical, and biotechnology industries. The company operates in segments, namely, Bruker Scientific Instruments (BSI) BioSpin, BSI CALID, BSI Nano, and Bruker Energy & Supercon Technologies (BEST) . The company generates maximum revenue from the BSI CALID segment. Geographically, it derives the maximum of its revenue from United States.

About TGTX TG Therapeutics Inc.

TG Therapeutics Inc is a fully integrated, commercial-stage biotechnology company focused on acquiring, developing, and commercializing novel treatments for B-cell diseases. In addition to a research pipeline, TG Therapeutics has received approval from the U.S. Food and Drug Administration (FDA) for BRIUMVI (ublituximab-xiiy) to treat adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, as well as approval from several regulatory agencies outside of the U.S. for BRIUMVI to treat adult patients with RMS who have active disease defined by clinical or imaging features.

Share on Social Networks: